NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial

Mar 10, 2022

Digital treatment device proven non-inferior to gold-standard eye patch treatment in multi-center randomized controlled study


NovaSight

NovaSight logo

AIRPORT CITY, Israel - March 10, 2022 - (Newswire.com)

NovaSight, a pediatric-focused eyecare company, announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia, commonly known as "lazy eye". The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved by CureSight digital treatment versus eye patching -- the current gold-standard-of-care treatment. This is the first-ever pivotal study in which a digital device was shown to be non-inferior to eye patching for amblyopia treatment in children

In addition to achieving the non-inferiority primary endpoint, the topline analyses from the pivotal study demonstrated that Best Corrected Visual Acuity (BCVA) improvement at week 16 was larger in the treatment group compared to the patching control group. In addition, a significant stereo acuity improvement was observed in both groups. No serious adverse events were observed in either treatment arms (CureSight or patching) and all non-serious adverse events were transient and self-limiting.

The study also evaluated adherence and patient satisfaction. The mean adherence to CureSight use during the study among subjects evaluated at the week 16 visit (N=43) was 93%, as measured by the CureSight's eye tracking system. In addition, 93% of parents reported that they are likely or very likely to choose the CureSight digital treatment over patching.

The pivotal clinical study was conducted in six medical centers, including Sheba Medical Center, which was ranked one of the top 10 best hospitals in the world by Newsweek, in 2021.

"We are delighted to have completed the CureSight study and further validate its safety and effectiveness as measured by visual acuity and stereoacuity improvement in comparison to patching and with a high safety profile and user satisfaction. Eye patching is effective when patients are compliant, however, patching is often associated with insufficient adherence due to the discomfort it brings to the patient and the social stigma that many children experience when wearing a patch," said NovaSight CEO Ran Yam. "The success of the CureSight study is a critical step toward bringing this treatment for lazy eye to children around the world and to potentially modernizing the standard of care."

CureSight is a digital device that trains the visual system to use both eyes simultaneously, while the user watches any streamed video content through red-blue treatment glasses. Using sophisticated algorithms and eye-tracking technology, CureSight blurs the center of vision of the image that is shown to the strong eye using real-time image processing. This encourages the brain to complete the image fine details from the amblyopic eye image and trains the two eyes to work as a team. The device is designed to be used at home, and it shares treatment reports with caregivers via a cloud portal. "Innovative solutions that make amblyopia treatment easier for patients to access and clinicians to prescribe and evaluate effectiveness are welcome and increasingly necessary," said Michael Repka, MD, MBA, Professor of Ophthalmology at Johns Hopkins University.

NovaSight has initiated a Series B financing round in addition to the $20 million the Israeli startup raised to date. Following on the recently granted CE mark approval for CureSight in Europe, completion of the CureSight pivotal trial represents a significant step forward to securing US FDA clearance. With three unique CPT codes for the CureSight treatment already effective since January 2022, NovaSight is poised to take the next step soon with the submission of its application for 510(k) clearance of the device. 

NovaSight also announced that, in addition to the CureSight, its CE marked EyeSwift®Pro system - a comprehensive eye-tracking based visual assessment system, which has a powerful portfolio of vision protocols such as myopia management and amblyopia monitoring - would be the subject of discussions with FDA regarding the premarket pathway to commercialization in the U.S. The EyeSwiftPro is the successor of the current generation EyeSwift® device which is distributed globally by EssilorLuxottica. 

NovaSight will be an exhibitor at the upcoming 47th annual meeting of the American Association for Pediatric Ophthalmology & Strabismus (AAPOS), from March 23 to 27, at the Westin Kierland Resort and Spa, Scottsdale, AZ. For more information or a demonstration of CureSight or EyeSwiftPro, see a NovaSight representative at Booth B-10.

About NovaSight

NovaSight is an Israeli company that focuses on bringing pediatric vision care into the digital age. Founded in 2016, NovaSight has experienced rapid growth by delivering complete end-to-end eye tracking-based solutions for accurate assessment and treatment of early vision disorders.

NovaSight offers two flagship products both ideally positioned for digital diagnostics and home treatment: The CureSight system is an eye tracking-based treatment for lazy eye designed to replace traditional eye patching. The EyeSwift®Pro system is a comprehensive vision assessment device that accurately and objectively screens for multiple vision impairments within seconds. Additional pipeline products not yet in distribution include the ActiveGlass® wearable solution for myopia (short-sightedness) control, targeted to bring significant advantages over existing solutions in order to combat the myopia global epidemic and TrackSight, a software solution that monitors real-time visual health and promotes myopia prevention during screens use.

NovaSight's management and advisory board are composed of executives, physicians, researchers, and key opinion leaders in the field of vision care.

Disclaimers

EyeSwift®Pro and CureSight are investigational devices, limited by federal (or United States) law to investigational use. 

Media Contacts:

Deb Holliday

412.877.4519

[email protected]

Jenny Goldman
Marketing Manager
[email protected]




Press Release Service by Newswire.com

Original Source: NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial

More News

GISBH: KPWKM prioritises swift reunification of rescued children with families

GISBH: KPWKM prioritises swift reunification of rescued children with families

Oct 15, 2024

KUALA LUMPUR: The immediate return of children rescued during Op Global to their parents and families is a top priority for the Ministry of Women, Family and Community Development (KPWKM). However, its minister, Datuk Seri Nancy Shukri said KPWKM must first ensure that the children’s parents and families can provide adequate and proper care. “For cases where the capability of the parents and families is clearly established, the reunification process can proceed without delay. In more complex situations, intervention programmes will be implemented to ensure the children’s and families’ best interests are safeguarded “The ultimate goal is to reunite these children with their families. However, before this can happen, several factors need to be carefully evaluated. This is not about denying anyone’s rights, but about ensuring the best interests of the children are upheld,” Nancy said during a minister’s briefing session on GISB Holdings Sdn Bhd (GISBH) in the Dewan Rakyat today. As of yesterday, 560 children – 283 boys and 277 girls – had been placed in safe custody after the Social Welfare Department (JKM) obtained a temporary court custody order for two months under Section 25(2)(a) of the Child Act 2001. Meanwhile, Nancy said the Task Force Profiling Team for Op Global found that 94.3 per cent of the 558 profiled children had at least one living biological parent, while 5.7 per cent had no parents or no available information on their parents. Health assessments showed that 51.6 per cent of the children were underweight, falling below the healthy Body Mass Index (BMI), while 46.1 per cent had a normal weight and the remaining children were classified as obese, she added. “Three children have been issued persons with disabilities (PwD) cards, while 27 others display symptoms of disability,” she added. Cognitive assessments were also conducted on 385 children aged seven and above, with 71.9 per cent (277 children) showing no signs of cognitive disorders, she said. “However, 20.26 per cent (78 children) displayed moderate cognitive disorders, while 7.79 per cent (30 children) were found to have severe cognitive impairments,” Nancy said.

Investigations ongoing into incident of empty Johor checkpoint counters with green lights on, blocked pathways

Investigations ongoing into incident of empty Johor checkpoint counters with green lights on, blocked pathways

Oct 15, 2024

PETALING JAYA: A surprise inspection by Johor Public Works, Transport, Infrastructure, and Communications committee chairman, Mohamad Fazli Mohamad Salleh recently found 17 Immigration counters at the Johor checkpoint empty. The inspection was conducted following a video circulating online showing the 17 empty counters at the checkpoint in Sultan Abu Bakar Complex (KSAB), triggering public backlash. He confirmed that the surprise inspection found that the incident actually occurred, Harian Metro reported. The video showed the empty counters, with green lights on however, the pathways were closed off to commuters. ALSO READ: Woman calls out Immigration officer for alleged rude behaviour Fazli then instructed that the green lights to be turned off to indicate that the lane is closed, to ensure no one is confused. “If there is no solid reason given regarding the incident, this can be considered intentional,” he was quoted as saying. On the other hand, Johor Immigration director Datuk Mohd Rusdi Mohd Darus said an internal probe will be conducted on the incident. ALSO READ: Woman expresses gratitude to Johor Immigration officers for returning lost RM1.5k “The internal investigation will determine whether the immigration officer handling the counter neglected their duties or intentionally left the counter without permission. “We will not tolerate this behaviour, and strict disciplinary action will be taken against them if they are found to have neglected their duties. “It is a violation of responsibility, and I take this issue seriously,“ he was quoted as saying.

Malaysia should seize opportunity in global medical devices market - Chang

Malaysia should seize opportunity in global medical devices market - Chang

Oct 15, 2024

KUALA LUMPUR: Malaysian innovators and manufacturers should seize the opportunity to tap into the immense potential of the global medical devices industry, which is projected to reach nearly US$800 billion by 2030, says Science, Technology and Innovation (MOSTI) Minister Chang Lih Kang. Chang noted that Malaysia had many high-quality products and innovators in the medical devices sector, with the government continuously encouraging and supporting industry players in research and development (R&D) and commercialisation efforts. “The market is vast, and we have plenty of room for success. To support R&D, of course, not limited to the medical devices industry, MOSTI offers various funding facilities, grants, matching grants, and equity where we invest in relevant startups,” he said. Chang said this to reporters after officiating the soft launch of INNOMed: Innovation Pitching Powered by PERANTIM, a key event in the International Medical Device Exhibition & Conference (IMDEC) 2024. Also present were Medical Device Authority (MDA) chief executive officer Dr P. Muralitharan, Malaysia Medical Devices Manufacturers Association (PERANTIM) president Johari Abu Kasim, and organising chairman of INNOMed, Dr Hyzan Mohd Yusof. Earlier in his speech, Chang said that under Malaysia’s New Industrial Master Plan (NIMP) 2030, the government aimed to foster synergies between the manufacturing and engineering sectors and the medical devices sector. This includes creating advanced inspection tools, solutions for imaging and endoscopy, implantable devices, and minimally invasive surgical tools. Meanwhile, Muralitharan told Bernama that, according to figures from the Department of Statistics Malaysia (DOSM), Malaysia’s total trade in medical devices, valued at RM25.61 billion from January to July this year, increased by 23.5 per cent compared to the same period in 2023 (RM20.74 billion). He added that the export of medical devices was valued at RM20.15 billion, an increase of 25.7 per cent compared to RM16.02 billion in 2023. In his speech, Dr Hyzan said that medical device innovation presented an opportunity to improve healthcare while boosting the economy, with the industry projected to reach nearly US$2 billion by 2025, making it one of the fastest-growing sectors. “By focusing on innovation, we can create high-skilled jobs, reduce our dependence on imported technologies, and position Malaysia as a global leader. Last year, we spent US$5 billion on medical devices, with 95 per cent being imports. Our goal is to reduce this to 50 per cent within five years,” he said. He also emphasised that close collaboration among universities, innovators, manufacturers, clinicians, and government agencies was key to ensuring that ideas and research transitioned smoothly from laboratories to clinical applications and into the hands of healthcare providers. INNOMed, themed “Unleashing the Power of Medical Technology: Shaping the Future of Healthcare,“ is organised by the MDA and will take place from Dec 10 to 12 at the Kuala Lumpur Convention Centre (KLCC).

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Utara Selatan

Bringing you from Utara to Selatan, we publish travel guides to make sure you will discover new places to visit in Malaysia and try all the local delicacies.

Newsletter